# Vosoritide therapy in children with achondroplasia under 5 years of age.

> PubMed lists PMID 39399714 in Translational pediatrics as Editorial, Comment, with publication-date metadata of 2024-09-11 (day precision). PeptideScanner associated the retained record with the identity slug vosoritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-39399714-vosoritide:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-10-15
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39399714-vosoritide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-39399714-vosoritide-v1.json
- Content SHA-256: `83a24fc780005430c9cf179109b8d5791f6948f860fc04c754019b4160c56a1a`

## Claims and source pins

### Headline

Vosoritide therapy in children with achondroplasia under 5 years of age. ([`pubmed-observation-pmid-39399714-2024-10-15-9a2858135bc6`](#source-pubmed-observation-pmid-39399714-2024-10-15-9a2858135bc6))

### Summary

PubMed lists PMID 39399714 in Translational pediatrics as Editorial, Comment, with publication-date metadata of 2024-09-11 (day precision). PeptideScanner associated the retained record with the identity slug vosoritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39399714-2024-10-15-9a2858135bc6`](#source-pubmed-observation-pmid-39399714-2024-10-15-9a2858135bc6))

### Paragraph 1

PubMed lists PMID 39399714 in Translational pediatrics as Editorial, Comment, with publication-date metadata of 2024-09-11 (day precision). PeptideScanner associated the retained record with the identity slug vosoritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39399714-2024-10-15-9a2858135bc6`](#source-pubmed-observation-pmid-39399714-2024-10-15-9a2858135bc6))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39399714-2024-10-15-9a2858135bc6`](#source-pubmed-observation-pmid-39399714-2024-10-15-9a2858135bc6))

## Sources

<a id="source-pubmed-observation-pmid-39399714-2024-10-15-9a2858135bc6"></a>
- **Vosoritide therapy in children with achondroplasia under 5 years of age. · retained source version 1:2024-10-15:current:9a2858135bc6c8ba0438e22075b540880f790ca352714f88aa9ef9a5f9ad9d08** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39399714/) (`pubmed-observation-pmid-39399714-2024-10-15-9a2858135bc6`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Vosoritide therapy in children with achondroplasia under 5 years of age." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-39399714-vosoritide-v1.json SHA-256: 83a24fc780005430c9cf179109b8d5791f6948f860fc04c754019b4160c56a1a.